Rivus posts a win for its experimental obesity drug in heart failure patients

Rivus Pharmaceuticals’ experimental cardiometabolic drug, HU6, nailed a mid-stage trial in obese patients with heart failure, finding that patients notched a statistically significant reduction in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Adrenomed presents new findings on its precision medicine treatment for septic shock with enibarcimab during Weimar Sepsis Update – Biotech Investments

EQS-News: Adrenomed AG / Key word(s): Study results Adrenomed presents new findings on its precision medicine treatment for septic shock with enibarcimab during Weimar Sepsis

September 9, 2023

Merck Merck KGaA acquires Mirus Bio

Mirus Bio’s GMP transfection re-agents complement Merck’s upstream bioprocessing portfolio. Credit: Merck KGaA, Darmstadt, Germany and/or its affiliates. Germany-based Merck KGaA has concluded the acquisition

August 2, 2024

Novel CRISPR-Cas9-Based Promising in ATTR Cardiomyopathy

CHICAGO – A CRISPR-Cas9-based investigational therapy was linked with a drop in serum transthyretin (TTR) levels in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), according

November 18, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.